Poniard Pharmaceuticals
Manufacturing · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
300 Elliott Ave W Ste 530, Seattle, Wash...Phone Number
(206) 281-7001Website
www.poniard.comRevenue
$15.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. Poniard's lead product candidate is picoplatin, a new generation platinum-based cancer therapy designed to treat solid tumors that are resistant to existing platinum-based therapies. Assuming receipt of shareholder approvals and satisfaction of other conditions to closing, the merger of Poniard and ALLOZYNE, Inc. will result in a Nasdaq-listed specialty pharmaceutical company focused on developing and commercializing therapeutics in the areas of autoimmune and inflammatory disease and cancer. The combined company is expected to seek a partnership for the continued development of picoplatin.Explore more
Poniard Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Poniard Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Poniard Pharmaceuticals recently announced quarterly report
Poniard Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Poniard Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Poniard Pharmaceuticals
Funding: Get notified immidiatlly once Poniard Pharmaceuticals has new funding data
Click to see if Poniard Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Poniard Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Poniard Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Poniard Pharmaceuticals
Compare insights from companies similar to Poniard Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Poniard Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Poniard Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Poniard Pharmaceuticals.
Poniard Pharmaceuticals News & Media
Poniard Pharmaceuticals and Allozyne Terminate Planned Merger
SAN FRANCISCO, CA, Dec 22, 2011 (MARKETWIRE via COMTEX) --Poniard Pharmaceuticals, Inc. (NASDAQ: PARDD) today announced that Poniard and Allozyne, Inc. have mutually agreed to terminate the Agreement and Plan of Merger and Reorganization dated June 22, 2011. The termination follows the parties' determination that the common stock of the combined company resulting from the proposed merger will not qualify for listing on The Nasdaq Capital Market, which is a condition to closing of thePoniard Pharmaceuticals Announces Shareholders Approve Merger With ALLOZYNE
1-for-40 Reverse Stock Split of Poniard Common Stock to Be Effective at 5:00 PM, Pacific Time, on November 22, 2011 SAN FRANCISCO, CA, Nov 21, 2011 (MARKETWIRE via COMTEX) -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that its shareholders have approved proposals to complete the previously announced merger with ALLOZYNE, Inc., including (i) the issuance of shares of Poniard common stock and resulting change of control of Poniard resulting from the merger and (ii)Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology
SAN FRANCISCO, Calif. – November 18, 2011 – Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard’s focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK. Under terms of the agreement, Poniard granted the licensee worldwide rights for the development andISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Three Leading Proxy Advisory Firms Recommend That Poniard Shareholders Vote "FOR" Important Proposals at Special Meeting of Shareholders to Be Held November 21 SAN FRANCISCO, CA, Nov 09, 2011 (MARKETWIRE via COMTEX) -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that ISS Proxy Advisory Services, the nation's leading independent proxy advisory firm, has recommended that Poniard shareholders vote "FOR" all proposals listed in the Company's proxy materials, including the proposal t
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Poniard Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. Poniard's lead product candidate is picoplatin, a new generation platinum-based cancer therapy designed to treat solid tumors that are resistant to existing platinum-based therapies. Assuming receipt of shar... Read More
